Relationship between insulin resistance and blood lipid and sport in patients with type II diabetes mellitus complicated with hypertension

Objective To study the relationship between insulin resistance and blood pressure and blood lipid in patients with type II diabetes mellitus complicated with hypertension.Methods The serum concentration of fasting glucose,insulin,lipids and the level of blood pressure were measured in 56 patients with type II diabetes mellitus complicated with hypertension.Results The insulin sensitivity index(ISI) decreased in patients with type II diabetes mellitus complicated with hypertension compared with the patients with type II diabetes mellitus with normal blood pressure(P< 0.05).A negative correlation with hypertension was found between ISI and SBP,DBP,TG,ApoB in patients with type II diabetes mellitus complicated with hypertension(P<0.05).There was a positive correlation between ISI and HDL in patients with type II diabetes mellitus complicated with hypertension(P<0.05).Conclusion Insulin resistance presents in patients of type II diabetes mellitus complicated with hypertension.Insulin resistance is the major cause of hypertension and lipid metabolic disturbance in patients with type II diabetes mellitus complicated with hypertension.

Carvedilol vs. metoprolol: A comparison of effects on endothelial function and oxidative stress in response to acute hyperglycemia in patients with type 2 diabetes and hypertension

Introduction: The GEMINI trial compared the effects of treatment with metoprolol versus carvedilol in patients with type 2 diabetes. Carvedilol demonstrated a more favorable effect on factors associated with the metabolic syndrome than metoprolol. We hypothesize that carvedilol will have additional beneficial effects on markers of inflammation, oxidative stress, and endothelial function than metoprolol. Methods: Twenty subjects were randomized to either carvedilol or metoprolol. Study procedures including assessment of metabolic parameters and endothelial function, while fasting and after a 75 g oral glucose tolerance were conducted at baseline and following 5 months of treatment. Results: Following 5 months of treatment, PAI-1 increased significantly from baseline in the metoprolol group. There were no changes in PAI-1 in the carvedilol group. While not reaching statistical significance, there was a trend toward worsening insulin resistance with metoprolol treatment compared to carvedilol treatment. Flow mediated vasodilation increased in both groups following the 2-hr OGGT during the baseline study. After five months of treatment, there was a non-significant increase in flow-mediated vasodilation under both fasting and post OGTT conditions in the carvedilol group compared to baseline. Conversely, there was no change in fasting flow mediated vasodilation in the metoprolol group. Additionally, metoprolol treatment blunted the increase in flow mediated vasodilation following OGGT compared to baseline (p < 0.05). Conclusion: Treatment with metoprolol was associated with adverse metabolic effects including increases in PAI-1 and trends toward worsening insulin resistance and endothelial function compared to treatment with carvedilol.

Prevalences of Diabetes and Hypertension and Their Relationship in Community Population of Jiangsu Province

To determine the prevalences of non-insulin-dependent-diabetes mellitus (NIDDM),impaired glucose tolerance (IGT) and hypertension on urban and rural communities of Jiangsu province,8734 subjects sampled from six areas of Jiangsu were investigated. Blood glucose of 2 h after oral administration of 75 g glucose (2 h BG) was measured. WHO criteria were used for the diagnosis of NIDDMand IGT. Meanwhile epidemiological data were collected. Blood pressure, height, weight, waist and hip girths were measured. The crude prevalence was found to be 5. 82% (men 4.62%,woman 6. 69%) for NIDDM, 5. 87% (men 5. 30%, women 6. 29% ) for IGT and 14. 72% (men 16. 50%, women 13. 43 % ) for hypertension in the population obove 20 years of age. Age-adjusted prevalence was 4. 63% for NIDDM, 5. 07 % for IGT and 11. 19% for hypertension. Age increase (>40 years), obesity (BMI≥27) and central fat distribution (WHR≥0.88) were the risk factors for both diabetes and hypertension. The subjects≥40 years of age and obesity were the high risk population of NIDDM, IGT and hypertension. They were the target population for theprevention and treatment of diabetes and hypertension in the community level. High prevalences of NIDDM,IGT and hypertension were observed in the community population in Jiangsu province. To reinforce the prevention and treatment of these disorders in the province is imperative.

Measurement of lumbar muscle glucose utilization rate can be as useful in estimating skeletal muscle insulin resistance as that of thigh muscle

Background: Skeletal muscle glucose utilization (SMGU) can be accessed by positron emission tomography (PET) and18F-FDG to characterize insulin resistance. The quantity of skeletal muscle in the lumbar is sufficient to indicate that SMGU in the lumbar (SMGU- lumbar) can be measured with18F-FDG PET of the chest instead of obtaining thigh muscle SMGU (SMGU-thigh). This would reduce PET scan time to avoid thigh muscle PET scan. This study was aimed to compare SMGU-lumbar and thigh muscle SMGU under insulin clamping to identify the validity of measurements of SMGU in the lumbar for studies of insulin resistance. Methods: Thirty-three patients underwent sequential dynamic18F-FDG PET of both the thoracic (37 min) and thigh region (22 min) during hyperinsulinemic euglycemic insulin clamping. Both SMGU-lumbar and SMGU-thigh were calculated by Patlak graphical analysis. Whole body insulin resistance was assessed by a whole body glucose disposal rate during hyperinsulinemic euglycemic insulin clamping. Input function was obtained from the time activity curve of the descending aorta and venous blood sampling as previously validated. Results: SMGU-thigh (0.0506 ± 0.0334 μmol/min/g) was comparable to SMGU-lumbar (0.0497 ± 0.0255 μmol/min/g). The Bland-Altman method of difference plot analysis showed a significant correlationship between SMGU- thigh and SMGU-lumbar (r = 0.506, p = 0.0028). There were seen very good significant correlationship between whole body glucose utilization rate in both thigh (r = 0.737, p = 0.0001) and lumbar (r = 0.772, p = 0.0001). Conclusion: These results support the validity of measuring SMGU-lumbar to estimate insulin resistance during PET imaging of the chest.

Functional imaging of skeletal muscle glucose metabolism by ¹⁸FDG PET to characterize insulin resistance in patients at high risk for coronary artery disease

Insulin resistance is associated with several coronary risk factors and is thought to play a critical role for the development of coronary artery disease. Insulin resistance has several causes, including an impaired skeletal muscle glucose utilization rate (SMGU), reduced peripheral blood flow, and altered fatty tissue metabolism, with SMGU being considered the most important. Nonetheless, insulin resistance has only been estimated by the glucose disposal rate (GDR) in previous studies. Methods: Skeletal muscle metabolic imaging with 18FDG and positron emission tomography (PET) was undertaken to measure SMGU during hyperinsulinemiceuglycemic clamping in 22 normotensive type-2 diabetics under no medications (T2- DM), 17 normotensive non-diabetic hypertriglyceridemics, 22 patients with hypertension, and 12 agematched controls. Whole body insulin resistance was assessed by the GDR during hyperinsulinemiceuglycemic insulin clamping. Results: The SMGU and GDR were significantly reduced in T2DM (32.1 ± 16.6 μmol/min/kg and 24.3 ± 13.0 μmol/min/kg, respectively), hypertriglyceridemics (36.5 ± 13.5 μmol/min/ kg and 22.7 ± 8.07 μmol/min/kg respectively) and patients with hypertension (35.4 ± 26.6 μmol/min/kg and 29.0 ± 9.90 μmol/min/kg, respectively) compared with controls (72.2 ± 44.1 μmol/min/kg and 43.0 ± 22.9 μmol/min/kg, p < 0.01, respectively). In all groups studied, SMGU was significantly correlated with GDR (r = 0.76, p < 0.01) and GDR (F = 13.9) was independently related to SMGU (r = 0.81, p < 0.01). Conclusion: Insulin resistance is significantly associated with SMGU to a similar degree among patients with T2DM, essential hypertension and hypertriglyceridemia. 18FDG PET functional imaging allows insulin resistance to be assessed.

Study of the Pathogenesis of Hypertension Associated with Non-Insulin Dependent Diabetes Mellitus

In order to study the pathogenesis of hypertension associated with noninsulin dependent diabetes mellitus (NIDDM), Plasma glucose, insulin levels at fasting and following an oral glucose load were measured. Na +K +pump and Ca 2+ pump activities of red blood cell membrane were also assessed. Hypertensive patients with normal or impaired glucose tolerance (NGT, or IGT) had hyperinsulinemia. Obese hypertensive patients also had hyperinsulinemia, while nonobese hypertensive patients had no hyperinsulinemia, but exhibited a delay in insulin response to oral glucose tolerance test (OGTT). In multivariate analysis, considering the factors of age, BMI and plasma glucose level, DBP were still positively related to both 30 min insulin level and IAUC, but negatively correlated to activities of Na +K +pump and Ca 2+ pump. These results demonstrated that a link between obesity, hpertension and NIDDM is the insulin resistance and/or hyperinsulinemia.

甘精胰岛素联合司美格鲁肽治疗血糖控制不佳的2型糖尿病合并高血压患者的效果

目的探讨甘精胰岛素联合司美格鲁肽注射液治疗血糖控制不佳的2型糖尿病(T2DM)合并高血压患者的效果及安全性。方法选取济南市妇幼保健院2021年7月至2023年2月收治的104例血糖控制不佳的T2DM合并高血压患者进行随机对照试验,采用随机数字表法将其分为对照组、研究组,各52例。对照组男30例,女22例,年龄(48.04±4.03)岁,体质量指数(24.08±3.15)kg/m^(2),T2DM病程(5.96±0.74)年,高血压病程(2.96±0.41)年;研究组男28例,女24例,年龄(47.13±4.48)岁,体质量指数(24.14±2.86)kg/m^(2),T2DM病程(6.13±0.85)年,高血压病程(3.03±0.38)年。对照组采用司美格鲁肽注射液治疗,研究组采用甘精胰岛素联合司美格鲁肽注射液治疗,均治疗3个月。采用t检验及χ^(2)检验对比两组治疗前后糖代谢情况、胰岛功能情况、脂代谢情况、血压情况、药物不良反应情况。结果两组治疗后空腹血糖(fasting blood glucose,FBG)、餐后2 h血糖(2 h postprandial blood glucose,2hPBG)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)、胰岛素抵抗指数(insulin resistance index,HOMA-IR)较治疗前均降低(均P<0.05),且研究组FBG、2hPBG、HbA1c、HOMA-IR均低于对照组[(5.91±0.76)mmol/L比(6.49±0.88)mmol/L、(8.47±0.96)mmol/L比(9.58±1.06)mmol/L、(5.27±0.73)%比(6.19±0.97)%、(4.53±0.69)比(5.39±0.86);t=3.935、5.774、9.724、5.624,均P<0.05]。两组治疗后三酰甘油(triglyceride,TG)、总胆固醇(total cholestero,TC)水平较治疗前均降低(均P<0.05),且研究组TG、TC水平低于对照组[(2.11±0.31)mmol/L比(2.49±0.39)mmol/L、(4.74±0.58)mmol/L比(5.29±0.75)mmol/L;t=5.500、4.183,均P<0.05]。两组治疗后低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)水平较治疗前均降低(均P<0.05),但两组治疗后LDL-C水平对比,差异无统计学意义(P>0.05)。治疗后,对照组收缩压、舒张压(121.03±14.28)mmHg(1 mmHg=0.133 kPa)、(84.01±9.62)mmHg,研究组(116.81±15.41)mmHg、(81.98±8.56)mmHg,差异均无统计学意义(均P>0.05)。对照组药物不良反应发生率为11.54%(6/52),研究组为13.46%(7/52),差异无统计学意义(P>0.05)。结论甘精胰岛素联合司美格鲁肽注射液治疗血糖控制不佳的T2DM合并高血压患者可有效控制患者糖脂代谢水平,改善患者胰岛功能,且安全性良好。

吲达帕胺联合缬沙坦改善高血压合并糖尿病生化指标的应用

目的:分析吲达帕胺联合缬沙坦对高血压合并糖尿病患者血压及肾功能指标的改善作用。方法:纳入确诊患者78例,2020年7月至2022年6月行回顾性研究,根据用药方式分组,2020年7月至2021年6月为对照组(n=39)使用缬沙坦,2021年7月至2022年6月为观察组,例数均等,联合吲达帕胺,对比两组临床疗效、用药前后血压、胰岛素抵抗程度和肾功能。结果:观察组总有效率更高,两组比较有统计学意义(P<0.05);两组用药前血压、胰岛素抵抗程度和肾功能比较无显著差异性(P>0.05);观察组经药物治疗后,舒张压、收缩压、胰岛素抵抗指数、血肌酐、尿素氮和尿微量白蛋白水平更低,胰岛素分泌指数和胰岛素敏感指数更高,两组比较有统计学意义(P<0.05)。结论:吲达帕胺联合缬沙坦治疗高血压合并糖尿病,可更好控制血压达标,降低胰岛素抵抗程度,对肾功能有改善作用,治疗效果明显提高。

2型糖尿病病人高血压与胰岛素抵抗的关系

目的 探讨高血压与胰岛素抵抗之间的关系。方法 ２型糖尿病高血压组１２３例，正常血压组１２０例。测定ＦＰＧ、ＦＩＮＳ、ＴＣ、ＴＧ、ＵＡ、ＭＡＵ、血压、计算ＢＭＩ。评价胰岛素抵抗和β细胞功能采用稳态模式评估法及改良胰岛素敏感性指数公式计算。结果 高血压组ＩＳＩ显著低于正常血压组，ＨＯＭＡ－βｃｅｌｌ、ＨＯＭＡ－ＩＲ显著高于正常血压组（Ｐ＜０．００５），正常体重者也有相同的结果（Ｐ＜０．０５）。两组ＩＳＩ与ＦＰＧ、ＦＩＮＳ、ＢＭＩ均呈显著负相关（Ｐ＜０．０５），高血压组ＩＳＩ与ＴＣ、ＴＧ、ＵＡ呈弱负相关（Ｐ＜０．５）。结论 ２型糖尿病伴高血压病人无论是否肥胖都存在胰岛素抵抗。肥胖病人胰岛素抵抗更为严重。

高血压与多种危险因素相关性分析

目的:研究原发性高血压(EH)患者与部分危险因素:体重指数(BMI)、血管紧张素转换酶(ACE)活性、脂类、血糖(GLU)、胰岛素(INS)水平及胰岛素抵抗(IR)间的相关关系。方法:127例EH患者及76例健康对照者,测定收缩压(SBP)、舒张压(DBP)、BMI。空腹GLU、INS、ACE、胆固醇(CHO)、甘油三脂(TG)、高密度胆固醇(HDL)、低密度胆固醇(LDL),和服糖后两小时CLU INS。计算出胰岛素敏感指数(ISIC)。结果:(1)127例EH患者血压与年龄,BMI、IR、TG、LDL和服糖后两小时GLU INS呈显著正相关;(2)血压与HDL、空腹GLU无相关性;(3)多因素回归分析显示IR和BMI是影响血压最重要的因素。结论:高血压患者存在胰岛素抵抗,当高血压合并肥胖时,IR更为明显。高血压病与糖尿病(DM)和心血管疾病间有许多共同的发病基础。

Ⅱ型糖尿病和高血压患者血液动力学改变的相关因素分析

目的 :探讨糖尿病和高血压血管并发症的发生机理。方法 :分别测定高血压 (HT)组、Ⅱ型糖尿病 (NID DM)组及Ⅱ型糖尿病合并高血压组和对照组的胰岛素水平、血脂、心脏彩超和血液流变学指标。结果 :3个试验组的周围总阻 (TPR)、甘油三脂 (TG)和胰岛素面积 (InsS)均明显增高 ,其中HT组和NIDDM合并HT组的左室收缩期峰值室壁应力 (PSS)也明显增高 ;NIDDM合并HT组InsS明显高于其他三组 ;三试验组的PSS、TPR、TG与各自InsS分别呈正相关 ;3个试验组的全血粘度 (ηb)值明显增高 ,且TPR与全血高切粘度(ηbH)、全血低切粘度 (ηbL)呈显著正相关。结论 :高血脂、高血粘度。

老年阻塞性睡眠呼吸暂停综合征与高血压及胰岛素抵抗的相关性研究

目的探讨阻塞性睡眠呼吸暂停综合征(OSAS)与高血压及胰岛素抵抗(IR)的关系。方法随机选择符合OSAS患者48例作为OSAS组,并分为高血压组(28例)和正常血压组(20例)2个亚组,同期选择无OSAS的高血压患者30例作为单纯高血压组,健康体检者26例作为正常对照组,均进行整夜睡眠呼吸监测(>7 h),并记录睡眠呼吸暂停低通气指数(AHI)等;空腹血糖(FPG)及空腹胰岛素(FINS)测定,对患者进行24 h的动态血压监测并进行相关分析。结果与单纯高血压组比较,高血压组患者非杓形血压比例和脉压均明显升高,差异有统计学意义(P<0.05,P<0.01)。OSAS组患者的FPG、FINS水平及胰岛素抵抗指数(HOMA-IR)均明显高于正常对照组,差异有统计学意义(P<0.05);OSAS患者的AHI与FINS和HOMA-IR均呈正相关。结论 OSAS与IR存在独立的相关性,可能通过IR导致并进一步加重心血管疾病的发生和发展。

糖尿病病合并高血压或高脂血症的胰岛素敏感性探讨

目的:探讨2型糖尿病患者在合并高血压或高脂血症时的胰岛索抵抗(IR)。方法:采用胰岛素敏感指数(空腹血糖、空腹胰岛素乘积的倒数),对37例糖尿病合并高血压组和31例糖尿病合并高脂血症组及63例单纯糖尿病组进行比较。结果:糖尿病合并高血压组胰岛素敏感指数大于单纯糖尿病组(P<0.05)。结论:本研究提示糖尿病合并高血压的患着比未合并高血压的患者存在着更为显著的胰岛素抵抗。

替米沙坦对2型糖尿病合并高血压患者血清APN、TNF-α及胰岛素抵抗的影响

目的观察替米沙坦对2型糖尿病合并高血压患者血清脂联素(APN)、肿瘤坏死因子(TNF-α)的变化及其对胰岛素抵抗的影响。方法 80例2型糖尿病合并高血压患者随机分为替米沙坦组和对照组,每组40例。在口服降糖药基础上,替米沙坦组给予替米沙坦片治疗,对照组给予氨氯地平片治疗。观察治疗前、后的血清APN、TNF-α浓度,并观察血压和胰岛素抵抗指数(IRI)水平。结果所有患者在治疗10周后血压均降至140/90 mmHg以下,而两组SBP、DBP比较,差异无统计学意义(P>0.05)。治疗前两组APN、TNF-α、HOMA-IR水平比较,差异无统计学意义(P>0.05)。治疗10周后,替米沙坦组外周血APN含量较对照组明显升高(P<0.05),TNF-α含量较对照组明显降低(P<0.05),HOMA-IR较对照组明显降低(P<0.05)。结论采用替米沙坦治疗2型糖尿病合并高血压患者,在升高血清APN浓度和降低TNF-α浓度的同时,具有改善胰岛素抵抗的作用。

胰岛素抵抗、血脂与老年2型糖尿病合并高血压的关系

目的 探讨老年 2型糖尿病 (DM)合并高血压患者与胰岛素抵抗及血脂的关系。方法 选择老年 2型 DM合并高血压患者 39例 ,无高血压的 DM患者 30例 ,无 DM的原发性高血压患者 2 1例 ,测定三组受试者血脂、空腹胰岛素、血糖 ,计算胰岛素抵抗指数 (HOMA- IR)和胰岛β细胞功能指数 (HOMA- IS)。结果 DM合并高血压组 HOMA- IR明显高于无高血压的 DM组 (P <0 .0 1) ,DM组明显高于无 DM的高血压组 (P <0 .0 1) ;DM合并高血压组血清甘油三酯 (TG)、血糖及糖化血红蛋白水平均高于其余两组。结论 老年 2型 DM患者存在胰岛素抵抗 ,胰岛素抵抗在 DM合并高血压患者中更为显著 ,血清 TG水平升高与老年 2型

2型糖尿病合并高血压患者血管内皮损伤及相关因素分析

目的:探讨2型糖尿病(T2DM)、高血压病(EH)及二者并发对血管内皮功能的影响及与之相关的因素,为防治T2DM合并EH患者内皮损伤提供新的依据及治疗指导。方法:采用酶联免疫吸附双抗体夹心法测定T2DM、EH、T2DM+EH患者血浆内皮损伤标志物血管性血友病因子(vWF)百分含量(vWF%),并与对照(NC)组进行比较。结果:vWF%T2DM组(115.81±38.56)%、EH组(112.97±32.47)%、T2DM+EH组(133.77±42.75)%均高于NC组(92.29±23.97)%;T2DM+EH组分别高于T2DM组、EH组,差异有统计学意义(P<0.05或P<0.01)。NC组BMI,T2DM组FIN、HbA1c,EH组收缩压(SBP),T2DM+EH组SBP、HbA1c进入影响血浆vWF%独立相关因素多元逐步回归分析方程。结论:T2DM、EH患者存在内皮功能损伤。NC组BMI;T2DM组FIN、HbA1c;EH组SBP;T2DM+EH组SBP、HbA1c是影响血浆vWF%的独立相关因素。

胰岛素抵抗与2型糖尿病体位性低血压的关系

目的 探讨 2型糖尿病 (DM )及糖尿病合并高血压 (DMH)患者发生体位性低血压 (PH) ,及其与糖尿病神经病变、高胰岛素血症和胰岛素抵抗 (IR)的关系。方法 DM及DMH患者各 3 0例。检测立卧位血压、自主及外周神经功能及血清胰岛素和血糖浓度 ,并计算胰岛素敏感指数。结果 单纯DM患者 40 %发生PH ,而DMH患者发生PH者达 67% ,两者之间差异非常显著 (P <0 .0 1)。DM合并PH和DMH合并PH患者的立卧位收缩压和舒张压变化幅值明显高于单纯DM患者 (P <0 .0 1) ,如DM同时合并高血压和PH者其腓总神经和腓浅神经等的传导速度明显低于单纯DM (P <0 .0 5 ) ,但体位性心率变化的差值、体重指数 (BMI)及空腹和餐后 2h血糖浓度在 3组中差别无显著性。DMH和PH者的血胰岛素浓度显著高于、而胰岛素敏感指数显著低于单纯DM患者 (P<0 .0 1) ,DMH合并PH患者收缩压下降幅值与空腹血胰岛素浓度呈显著正相关 (r=0 .689,P <0 .0 1)。结论 DMH更易发生PH ,并加重外周神经的损害。DM患者伴PH存在明显的胰岛素抵抗 (IR)和高胰岛素血症 ,如同时合并高血压 。

2型糖尿病合并高血压患者瘦素水平与胰岛素抵抗和颈动脉内中膜厚度的关系

对65例糖尿病合并高血压患者和60例非糖尿病者的研究显示,2型糖尿病合并高血压患者瘦素水平与胰岛素抵抗和颈动脉内中膜厚度正相关。

锌α2糖蛋白与胰岛素抵抗相关疾病关系的研究进展

随着现代生活方式及饮食习惯的改变,疾病谱的重心逐渐转变为慢性非感染性疾病。心血管疾病、糖脂代谢紊乱、肥胖、代谢综合征、多囊卵巢综合征等疾病均与胰岛素抵抗有关。胰岛素抵抗是慢性非感染性疾病的重要组成部分,患病人群众多,严重影响其生活质量。锌α2糖蛋白(Zinc-α2-Glycoprotein,ZAG)是新近发现的一种具有调节体质量和改善胰岛素敏感性的脂肪因子,因其与胰岛素抵抗相关疾病关系密切逐渐受到人们的重视。近年来大量临床实验研究ZAG与胰岛素抵抗的关系,本文拟这些研究进展做一综述。

运动性高血压与2型糖尿病及胰岛素抵抗的相关性研究

目的 探讨运动性高血压（exercise hypertension,EH）与2型糖尿病（type 2 diabetes mellitus,T2DM）及胰岛素抵抗的关系。方法 选取2010年8月至2013年7月在遵义市第一人民医院内分泌科门诊和内分泌科住院部初诊的2型糖尿病（T2DM）患者109例作为病例组,匹配年龄、性别后以同期43例健康体检志愿者作为对照组。以Bruce运动方案做次级量症状限制性运动试验,比较分析T2DM患者和对照组运动性高血压的发生率;采用HOMA-IR法评估胰岛素抵抗。应用独立样本t检验和多因素Logistic回归分析,探讨T2DM患者运动性高血压与胰岛素抵抗、糖化血红蛋白、年龄、血脂等的关系。结果 病例组运动试验前后收缩压变化幅度显著高于对照组,而且运动性高血压的发生率也明显高于对照组,差异均具有统计学意义（P〈0.05）。t检验结果显示,EH组HOMA-IR指数显著高于非EH组,差异具有统计学意义（P=0.013）;多因素Logistic回归分析,结果显示HOMA-IR指数进入方程,提示胰岛素抵抗可能是运动性高血压EH发生的危险因素,OR及相应95%置信区间为1.48（1.03-2.12）。结论 T2DM可增加运动性高血压的发生风险;与无运动性高血压的T2DM患者相比,运动性高血压患者可能具有较高的胰岛素抵抗。